The determinants of tumour immunogenicity
暂无分享,去创建一个
Eli Gilboa | E. Gilboa | E. Jaffee | P. Coulie | T. Blankenstein | Thomas Blankenstein | Elizabeth M. Jaffee | Pierre G. Coulie
[1] M. Burnet. IMMUNOLOGICAL FACTORS IN THE PROCESS OF CARCINOGENESIS. , 1964, British medical bulletin.
[2] G. Klein,et al. Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. , 1977, Proceedings of the National Academy of Sciences of the United States of America.
[3] L. Thomas. On immunosurveillance in human cancer. , 1982, The Yale journal of biology and medicine.
[4] A. Rimm,et al. Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.
[5] P. Chomez,et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.
[6] P. Bruggen,et al. Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.
[7] H. Schreiber,et al. Antigenic cancer cells that escape immune destruction are stimulated by host cells. , 1995, Cancer research.
[8] D. Hanahan,et al. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. , 1998, Cancer research.
[9] M Cohn,et al. A minimal model for the self-nonself discrimination: a return to the basics. , 2000, Seminars in immunology.
[10] R. Schreiber,et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.
[11] Yao-Tseng Chen,et al. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy , 2002, Immunological reviews.
[12] R. Schreiber,et al. Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.
[13] T. Schumacher,et al. T-cell-receptor gene therapy , 2002, Nature Reviews Immunology.
[14] N. Restifo,et al. Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.
[15] O. Jose. Melvin Cohn The immune system : a weapon of mass destruction invented by evolution to even the odds during the war of the DNAs , 2002 .
[16] J. Krauss. A return to basics , 2002 .
[17] J. Becker,et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth , 2002, Nature Network Boston.
[18] Melvin Cohn,et al. The immune system: a weapon of mass destruction invented by evolution to even the odds during the war of the DNAs , 2002, Immunological reviews.
[19] M. Dewhirst,et al. Synergy between tumor immunotherapy and antiangiogenic therapy. , 2003, Blood.
[20] C. Uyttenhove,et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.
[21] B. Brors,et al. Medullary Epithelial Cells of the Human Thymus Express a Highly Diverse Selection of Tissue-specific Genes Colocalized in Chromosomal Clusters , 2004, The Journal of experimental medicine.
[22] R. Schreiber,et al. The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.
[23] T. Blankenstein,et al. A cancer immunosurveillance controversy , 2004, Nature Immunology.
[24] George Coukos,et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.
[25] C. Huber,et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[26] Sandro Sorella,et al. Recent progress with the , 2005 .
[27] G. Willimsky,et al. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance , 2005, Nature.
[28] G. Willimsky,et al. Tumor‐induced antibodies resemble the response to tissue damage , 2005, International journal of cancer.
[29] L. Zitvogel,et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death , 2005, The Journal of experimental medicine.
[30] E. Jaffee,et al. Immunotherapy for pancreatic cancer — science driving clinical progress , 2005, Nature Reviews Cancer.
[31] C. Blank,et al. Immune resistance orchestrated by the tumor microenvironment , 2006, Immunological reviews.
[32] C. Klebanoff,et al. CD8+ T‐cell memory in tumor immunology and immunotherapy , 2006, Immunological reviews.
[33] E. Jaffee,et al. Mechanisms of immune evasion by tumors. , 2006, Advances in immunology.
[34] Thierry Boon,et al. Human T cell responses against melanoma. , 2006, Annual review of immunology.
[35] Thomas Pradeu,et al. On the definition of a criterion of immunogenicity , 2006, Proceedings of the National Academy of Sciences.
[36] L. Zitvogel,et al. Cancer despite immunosurveillance: immunoselection and immunosubversion , 2006, Nature Reviews Immunology.
[37] I. Tannock,et al. Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.
[38] O. Lantz,et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. , 2005, Blood.
[39] Fabian Kiessling,et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction , 2008, Nature.
[40] P. Gimotty,et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy , 2008, Nature Medicine.
[41] Jianhong Cao,et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. , 2008, The New England journal of medicine.
[42] H. Stein,et al. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness , 2008, The Journal of experimental medicine.
[43] R. Offringa. Antigen choice in adoptive T-cell therapy of cancer. , 2009, Current opinion in immunology.
[44] David Allard,et al. Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.
[45] Srinivas Nagaraj,et al. Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.
[46] J. Blay,et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. , 2009, Cancer research.
[47] D. Busch,et al. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. , 2009, Blood.
[48] P. Muranski,et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells , 2009, Nature Medicine.
[49] L. Zitvogel,et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines. , 2010, Seminars in immunology.
[50] F. Garrido,et al. “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy , 2010, International journal of cancer.
[51] P. Courtoy,et al. A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. , 2010, Cancer research.
[52] T. Blankenstein,et al. Transgenic mice with a diverse human T cell antigen receptor repertoire , 2010, Nature Medicine.
[53] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[54] Erkki Ruoslahti,et al. Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs , 2010, Science.
[55] M. Kloor,et al. Immune evasion of microsatellite unstable colorectal cancers , 2010, International journal of cancer.
[56] P. Kantoff,et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.
[57] E. Gilboa,et al. Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay , 2010, Nature.
[58] J. McNamara,et al. Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[59] P. Coulie,et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. , 2011, Cancer research.
[60] J. Neefjes,et al. Towards a systems understanding of MHC class I and MHC class II antigen presentation , 2011, Nature Reviews Immunology.
[61] Jonathan W. Uhr,et al. Controversies in clinical cancer dormancy , 2011, Proceedings of the National Academy of Sciences.
[62] A. Maitra,et al. Tyrosine 23 Phosphorylation-Dependent Cell-Surface Localization of Annexin A2 Is Required for Invasion and Metastases of Pancreatic Cancer , 2011, PloS one.
[63] George Coukos,et al. Cancer immunotherapy comes of age , 2011, Nature.
[64] M. Weller,et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor , 2011, Nature.
[65] T. van Hall,et al. Strategies to counteract MHC-I defects in tumors. , 2011, Current opinion in immunology.
[66] G. Kroemer,et al. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. , 2011, Cancer research.
[67] C. Uyttenhove,et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase , 2012, Proceedings of the National Academy of Sciences.
[68] T. Blankenstein,et al. B‐cells and IL‐4 promote methylcholanthrene‐induced carcinogenesis but there is no evidence for a role of T/NKT‐cells and their effector molecules (Fas‐ligand, TNF‐α, perforin) , 2012, International journal of cancer.
[69] K. Rezvani,et al. Vaccination Strategies in Lymphomas and Leukaemias , 2011, Drugs.
[70] J. Delrow,et al. Rescued Tolerant CD8 T Cells Are Preprogrammed to Reestablish the Tolerant State , 2012, Science.
[71] C. Parker,et al. Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer , 2012, Journal of the National Cancer Institute.